Tandem Diabetes Care, Inc. (NASDAQ:TNDM) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of...
Tandem Diabetes Care (NASDAQ:TNDM), Inc. TNDM has been gaining on robust domestic and international pump sales and shipments. Its better-than-expected revenues in the fourth...
Tandem Diabetes Care (NASDAQ:TNDM), Inc. TNDM reported adjusted loss per share of 19 cents for second-quarter 2020, wider than the year-ago metric of a loss of 3 cents. However,...
Tandem Diabetes Care, Inc. is a medical device company. The Company is focused on the design, development, and commercialization of technology solutions for people living with diabetes. The Company's manufacturing, sales, and support activities principally focus on its flagship pump platform, the t:slim X2, and its complementary product offerings. Its t:slim X2 is based on Company's technology platform and is the smallest durable insulin pump available in the United States. The Company has commercially offered two different automated insulin dosing (AID) algorithms on t:slim X2, including Control-IQ technology, which is an advanced hybrid-closed loop feature, designed to help increase a user's time in their targeted glycemic range, and Food and Drug Administration (FDA) to deliver automatic correction boluses in addition to adjusting insulin to help prevent high and low blood sugar based on continuous glucose monitoring (CGM) readings.